Recursion Pharmaceuticals a News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.11.24	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery (GlobeNewswire)
07.11.24	A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals (Benzinga)
02.11.24	Is Recursion Pharmaceuticals a Millionaire-Maker Stock? (MotleyFool)
26.10.24	3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock (MotleyFool)
22.10.24	Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection (GlobeNewswire)
15.10.24	Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip? (MotleyFool)
02.10.24	Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma (GlobeNewswire)
20.09.24	Is Recursion Pharmaceuticals Stock a Buy? (MotleyFool)
08.09.24	Cathie Wood dreht sich Richtung Biotech: Neue Prioritäten bei ARK Invest? (finanzen.ch) Während Cathie Wood Unternehmen aus dem Sportdatenbereich offenbar den Rücken kehrt, hat sie eine neue Branche ins Visier genommen. So stehen Biotech-Aktien nun ganz weit oben auf der Liste von ARK Invest.» mehr
04.09.24	Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals (Benzinga)
03.09.24	Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session (Benzinga)
03.09.24	Recursion: REC-994 Meets Primary Endpoint Of Safety, Tolerability In 12-month Phase 2 Study (RTTNews)
03.09.24	Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On? (Benzinga)
03.09.24	Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability (GlobeNewswire)
30.08.24	Is Recursion Pharmaceuticals a Warren Buffett Stock? (MotleyFool)
18.08.24	The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. (MotleyFool)
17.08.24	Is Recursion Pharmaceuticals Stock a Buy? (MotleyFool)
11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
11.08.24	Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? (MotleyFool)
08.08.24	AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals (Benzinga)
08.08.24	Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities (GlobeNewswire)
07.08.24	Ausblick: Recursion Pharmaceuticals, A stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
06.08.24	Is Recursion Pharmaceuticals a Millionaire-Maker? (MotleyFool)
27.07.24	Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip? (MotleyFool)
14.07.24	Is Recursion Pharmaceuticals Stock a Buy? (MotleyFool)
13.07.24	1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell (MotleyFool)
27.06.24	Why Recursion Pharmaceuticals Stock Is Tumbling Thursday (Benzinga)
26.06.24	Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On? (Benzinga)
25.06.24	Recursion Pharmaceuticals Stock Is Moving Tuesday: What's Happening? (Benzinga)
24.06.24	What's Going On With Recursion Pharmaceuticals Stock Monday? (Benzinga)
17.06.24	Cathie Wood: NVIDIA-Bewertung nur unter bestimmten Voraussetzungen gerechtfertigt (finanzen.ch) ARK Invest-Gründerin Cathie Wood ist für ihr eher unglückliches Timing im Zusammenhang mit NVIDIA-Aktien bekannt. Dennoch lässt sie kaum eine Gelegenheit aus, um sich zu dem grossen Gewinner des KI-Hypes zu äussern - und das Potenzial ihrer alternativen KI-Favoriten zu betonen.» mehr
07.06.24	Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim (MotleyFool)
02.06.24	Is Recursion Pharmaceuticals Stock a Millionaire-Maker? (MotleyFool)
13.05.24	Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism (Benzinga)
10.05.24	Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews (Benzinga)
09.05.24	Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know (Benzinga)
08.05.24	Ausblick: Recursion Pharmaceuticals, A verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Recursion Pharmaceuticals, Inc Registered Shs -A-

Aktien Top/Flop

Meistgelesene Nachrichten